We conclude that activation of gastric ERs with E2 and/or selective ER modulators are a promising frontier for managing the variations in gastric motility observed in obesity-induced diabetes in addition to inflammation and oxidative stress. The gene discussed is ESR1; the disease is obesity due to melanocortin 4 receptor deficiency.